ArticleCancer medicine2021
Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Association of baseline eosinophil counts with clinical prognosis in cancer patients undergoing immune checkpoint inhibitor therapy.iScience · 2026Article
- Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026Review
- Baseline and early changes in eosinophil count and neutrophil-to-eosinophil ratio predict outcomes in metastatic renal cell carcinoma treated with nivolumab.Scientific reports · 2025Article
- Peripheral eosinophils and immunotherapy response in patients with recurrent or metastatic HNSCC.Scientific reports · 2025Article
- Integrating Novel and Classical Prognostic Factors in Locally Advanced Cervical Cancer: A Machine Learning-Based Predictive Model (ESTHER Study).Journal of personalized medicine · 2025Article
- Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab.Acta oncologica (Stockholm, Sweden) · 2024Article
- The prognostic impact of peripheral blood eosinophil counts in metastatic renal cell carcinoma patients treated with nivolumab.Clinical and experimental medicine · 2024Article
- Article
- Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinoma.Exploration of targeted anti-tumor therapy · 2024Review
- Review
- Low expression of SLC34A1 is associated with poor prognosis in clear cell renal cell carcinoma.BMC urology · 2023Article
- C1QC is a prognostic biomarker with immune-related value in kidney renal clear cell carcinoma.Frontiers in genetics · 2023Article
- Review
- Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.Nature immunology · 2022Review
- Article
- Article
- Article
- Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.Frontiers in oncology · 2022Article
- Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite improvements in the management of renal cell carcinomas (RCC) with the advent of immunotherapy, only a few patients respond to these treatments. Predictors of response to nivolumab are currently being investigated but are still lacking. AIM OF THE STUDY: To evaluate eosinophil levels and their variations during treatment as an accurate biomarker for outcome in metastatic RCC treated with nivolumab.
methodsA retrospective analysis was carried out for patients with metastatic RCC treated with nivolumab. Absolute eosinophil counts, their variation, and relative change were evaluated at six weeks. Relative eosinophil change was categorized in three groups (≥10%-decrease, no change, ≥10%-increase). Univariable and multivariable analyses were performed to determine whether eosinophils and their variations were prognostic markers for response at the first scan evaluation, progression-free survival, and overall survival.
resultsSixty-five patients aged on average 66 years, 68% men, and 77% with good or intermediate International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group were included. The median follow-up was 16.6 months. Median overall survival (OS) was not reached for good prognosis and was 22.5 and 6.5 months for intermediate and poor prognosis, respectively. An increase in eosinophils and relative eosinophil change at six weeks of nivolumab was associated with a good response to immunotherapy (p = 0.012 and p = 0.024 respectively). In the group of patients with a 10%-decrease in relative change, PFS reduced significantly compared to the other groups (p = 0.0044 with the 10%-increase group and p = 0.03 with the no-change group). This relative increase was independent of IMDC risks factors for better OS (HR = 3.3 [1.45-7.4]; p = 0.004). The eosinophil baseline level was not associated with response to treatment.
conclusionEosinophil levels and relative eosinophil change at 6 weeks might be good prognostic markers for response to nivolumab for metastatic RCC, and were associated with better PFS and OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.